Efficacy of nalbuphine as a parenteral analgesic for the treatment of painful episodes in children with sickle cell disease.
Painful episodes of sickle cell disease remain a source of frustration to patients and health care providers because of the lack of interventions to prevent or control them. Nalbuphine is a potent semisynthetic agonist/antagonist analgesic. We report our experience using nalbuphine as a treatment for painful episodes of sickle cell disease in children. The efficacy of subcutaneous/intramuscular nalbuphine is compared with intramuscular meperidine by a retrospective review of hospitalizations for sickle cell painful episodes. Nalbuphine is as effective as meperidine for the treatment of these episodes. We conclude that nalbuphine is a feasible and effective analgesic and a reasonable treatment option for patients with sickle cell disease experiencing painful episodes.
Woods
G M
GM
Department of Pediatrics, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine 64108.
Parson
P M
PM
Strickland
D K
DK
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D009266:Nalbuphine / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology
D009266:Nalbuphine